This bill amends the Controlled Substance, Drug, Device and Cosmetic Act to include medetomidine in Schedule III of controlled substances. It specifies that medetomidine, along with any compound or preparation containing it, is classified as a controlled substance unless used in certain approved manners, such as for nonhuman species under specific federal regulations or for pharmaceutical compounding by licensed professionals. The bill outlines various conditions under which medetomidine is exempt from being classified as a controlled substance, ensuring its availability for veterinary use and pharmaceutical applications.

Additionally, the bill mandates secure storage provisions for both medetomidine and xylazine, requiring veterinarians to comply with existing regulations for the storage and protection of these substances. This amendment aims to enhance the regulation of these drugs while ensuring that they remain accessible for legitimate medical and veterinary purposes. The act is set to take effect immediately upon passage.

Statutes/Laws affected:
Printer's No. 1082 (Jul 24, 2025): P.L.233, No.64